PL2930184T3 - Przeciwciała DKK-1 - Google Patents

Przeciwciała DKK-1

Info

Publication number
PL2930184T3
PL2930184T3 PL15159780T PL15159780T PL2930184T3 PL 2930184 T3 PL2930184 T3 PL 2930184T3 PL 15159780 T PL15159780 T PL 15159780T PL 15159780 T PL15159780 T PL 15159780T PL 2930184 T3 PL2930184 T3 PL 2930184T3
Authority
PL
Poland
Prior art keywords
dkk
antibodies
Prior art date
Application number
PL15159780T
Other languages
English (en)
Inventor
Marcio Chedid
Ryan James Darling
Rachelle Jeanette Galvin
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2930184T3 publication Critical patent/PL2930184T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15159780T 2009-04-10 2010-04-06 Przeciwciała DKK-1 PL2930184T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
EP15159780.4A EP2930184B1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies
PCT/US2010/030039 WO2010117980A1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies
EP10712681.5A EP2417158B9 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (1)

Publication Number Publication Date
PL2930184T3 true PL2930184T3 (pl) 2019-10-31

Family

ID=42199718

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10712681T PL2417158T3 (pl) 2009-04-10 2010-04-06 Przeciwciała DKK-1
PL15159780T PL2930184T3 (pl) 2009-04-10 2010-04-06 Przeciwciała DKK-1
PL19156509T PL3514173T3 (pl) 2009-04-10 2010-04-06 Przeciwciała DKK-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10712681T PL2417158T3 (pl) 2009-04-10 2010-04-06 Przeciwciała DKK-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19156509T PL3514173T3 (pl) 2009-04-10 2010-04-06 Przeciwciała DKK-1

Country Status (30)

Country Link
US (1) US8148498B2 (pl)
EP (3) EP2417158B9 (pl)
JP (1) JP5759977B2 (pl)
KR (3) KR20110124364A (pl)
CN (1) CN102388065B (pl)
AR (1) AR075989A1 (pl)
AU (1) AU2010234611B2 (pl)
BR (1) BRPI1014157B1 (pl)
CA (1) CA2758252C (pl)
CY (3) CY1119399T1 (pl)
DK (3) DK3514173T3 (pl)
EA (1) EA021401B1 (pl)
ES (3) ES2644244T3 (pl)
HR (3) HRP20171400T1 (pl)
HU (3) HUE043904T2 (pl)
IL (1) IL214845A (pl)
LT (3) LT2417158T (pl)
ME (2) ME03378B (pl)
MX (1) MX2011010707A (pl)
NZ (1) NZ595011A (pl)
PL (3) PL2417158T3 (pl)
PT (3) PT3514173T (pl)
RS (3) RS58612B1 (pl)
SG (1) SG175244A1 (pl)
SI (3) SI2417158T1 (pl)
TR (1) TR201907261T4 (pl)
TW (1) TWI546079B (pl)
UA (1) UA103916C2 (pl)
WO (1) WO2010117980A1 (pl)
ZA (1) ZA201107256B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596274A (en) 2009-05-12 2013-11-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
US10584174B2 (en) 2015-05-18 2020-03-10 Eli Lilly And Company Anti-Dkk-1-anti-RANKL bispecific antibody compounds
KR20180054639A (ko) * 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CA3041325A1 (en) * 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
KR20210044783A (ko) * 2018-07-11 2021-04-23 모멘타 파머슈티컬스 인코포레이티드 CTLA-4 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
CA3151228A1 (en) * 2019-09-19 2021-03-25 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
EP4061419A1 (en) * 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
CA3206789A1 (en) * 2021-02-05 2022-08-11 Gregory A. Demopulos Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
WO2023143444A1 (zh) * 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途
IL318268A (en) 2022-07-12 2025-03-01 Leap Therapeutics Inc Combined treatment
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69842225D1 (de) 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
JP2005512508A (ja) 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
MXPA04004378A (es) 2001-11-07 2004-09-10 Univ Arkansas Diagnostico, prognosis e identificacion de objetivos terapeuticos potenciales de mieloma multiple basado en el perfilado de expresion de genes.
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
JP2007525953A (ja) 2003-06-06 2007-09-13 ワイス 骨リモデリングを調節する物質を同定するための方法および材料、ならびにそれによって同定された物質
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CA2677356A1 (en) * 2007-02-08 2008-08-14 Zhiqiang An Antibodies specific for dkk-1
EP2427490A1 (en) * 2009-05-07 2012-03-14 Novartis AG Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both

Also Published As

Publication number Publication date
DK2417158T3 (en) 2017-10-16
KR20140090273A (ko) 2014-07-16
KR101461362B1 (ko) 2014-11-13
CY1124412T1 (el) 2022-07-22
IL214845A0 (en) 2011-11-30
EP3514173B8 (en) 2021-08-04
SI2417158T1 (sl) 2017-10-30
SI2930184T1 (sl) 2019-06-28
EA021401B1 (ru) 2015-06-30
CA2758252C (en) 2015-02-24
RS58612B1 (sr) 2019-05-31
UA103916C2 (xx) 2013-12-10
ZA201107256B (en) 2013-03-27
EP2930184B1 (en) 2019-03-27
HRP20190643T1 (hr) 2019-05-31
CN102388065B (zh) 2014-09-03
CY1121637T1 (el) 2020-07-31
HUE034625T2 (en) 2018-02-28
SG175244A1 (en) 2011-12-29
ME02798B (me) 2018-01-20
TR201907261T4 (tr) 2019-06-21
HRP20171400T1 (hr) 2017-11-03
CN102388065A (zh) 2012-03-21
CA2758252A1 (en) 2010-10-14
RS62214B1 (sr) 2021-09-30
AR075989A1 (es) 2011-05-11
EP3514173B1 (en) 2021-06-23
DK3514173T3 (da) 2021-08-02
EP2417158B1 (en) 2017-08-02
CY1119399T1 (el) 2018-02-14
LT2417158T (lt) 2017-10-10
PL2417158T3 (pl) 2017-12-29
PL3514173T3 (pl) 2022-01-17
WO2010117980A1 (en) 2010-10-14
EP2417158A1 (en) 2012-02-15
ES2887176T3 (es) 2021-12-22
EP2417158B9 (en) 2017-12-06
TWI546079B (zh) 2016-08-21
EP2930184A1 (en) 2015-10-14
PT3514173T (pt) 2021-08-16
EP3514173A1 (en) 2019-07-24
HRP20211343T1 (hr) 2021-11-26
US20100260754A1 (en) 2010-10-14
HUE043904T2 (hu) 2019-09-30
IL214845A (en) 2016-06-30
NZ595011A (en) 2013-05-31
PT2417158T (pt) 2017-10-23
RS56505B1 (sr) 2018-02-28
AU2010234611B2 (en) 2013-02-07
DK2417158T4 (da) 2018-01-29
JP2012523417A (ja) 2012-10-04
PT2930184T (pt) 2019-06-17
KR20140033523A (ko) 2014-03-18
LT3514173T (lt) 2021-09-10
BRPI1014157B1 (pt) 2022-01-18
US8148498B2 (en) 2012-04-03
TW201100101A (en) 2011-01-01
SI3514173T1 (sl) 2021-09-30
AU2010234611A1 (en) 2011-10-20
HUE055376T2 (hu) 2021-11-29
MX2011010707A (es) 2012-02-28
BRPI1014157A2 (pt) 2020-09-29
LT2930184T (lt) 2019-05-10
ME03378B (me) 2020-01-20
KR20110124364A (ko) 2011-11-16
ES2644244T3 (es) 2017-11-28
EA201171237A1 (ru) 2012-04-30
JP5759977B2 (ja) 2015-08-05
ES2728911T3 (es) 2019-10-29
DK2930184T3 (da) 2019-05-13

Similar Documents

Publication Publication Date Title
DK3514173T3 (da) DKK-1-antistoffer
PT2406284T (pt) Anticorpos anti-bcma
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
EP2473531A4 (en) Anti-gitr antibodies
BRPI1011005A2 (pt) anticorpos anti-epcam
DK2414015T3 (da) Laryngoskopsystem
DE112010002949A5 (de) Kupplungstastpunkte
EP2491340A4 (en) TELEMETRY PHOTOGRAPHIC APPARATUS
EP2509489A4 (en) SPRINKLER FOR EARLY HEEL REMOVAL
EP2446176A4 (en) CYLINDER SEAL
DE112009005462T8 (de) Lenkungsssteuervorrichtung
FI20095754A0 (fi) Tuloilmalaite
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
FI20095698A0 (fi) Kaavinterämateriaali
FI8691U1 (fi) Aukirullain
DE102009034429A8 (de) Flachantenne
FI20090173A0 (fi) Pystypuun karsintalaite
DK2517018T3 (da) Biomarkører
FI20096331A0 (fi) Antibodin käyttö
TH0901003923A (th) แอนติบอดีหลายความจำเพาะ
TH0901003733A (th) องค์ประกอบเชิงภูมิคุ้มกัน
ES1069841Y (es) Arqueta
FI20095898A0 (fi) Kuivajääpuhallin
FI20090400A0 (fi) Saksilava
FI20096102A0 (fi) Hirsirakenne